Avidity Biosciences, Inc

In operation since 2003, NexBio is involved in the development and commercialization of biopharmaceuticals to prevent and treat life-threatening human diseases. It develops Fludase, which is a drug candidate for the prophylaxis and treatment of respiratory infections. The company is also involved in the preclinical development of Viradin, which is an intravenous therapeutic product for sepsis and septic shock, as well as viral hemorrhagic fever caused by various pathogens. NexBio offers TOSAP, which is a proprietary formulation technology capable of creating microspheres and nanospheres for drug delivery.

EpicentRx Inc is a biotechnology company based in La Jolla, CA, specializing in the development of innovative cancer therapies. Led by a team of experienced professionals, including Chief Executive Officer Dr. Tony Reid and Chief Scientific Officer Dr. Franck Brinkhaus, the company is dedicated to advancing its pipeline of cutting-edge technologies, such as the AdAPT Platform and PRETECT Platform, to revolutionize cancer treatment. With a focus on viral therapy and a commitment to scientific excellence, EpicentRx Inc aims to bring novel solutions to patients in need. Their team, which includes Chief Medical Officer Dr. Bryan Oronsky and Vice President of Viral Therapy Dr. Chris Larson, is dedicated to pushing the boundaries of cancer research and developing innovative therapies that have the potential to transform the lives of patients worldwide.Generated from the website

Boundless Bio is a clinical stage precision oncology company based in La Jolla, CA, dedicated to delivering innovative therapies for patients with intractable oncogene amplified cancers. Their groundbreaking science focuses on targeting extrachromosomal DNA (ecDNA), a key enabling mechanism in cancer, and turning it into a vulnerability, offering new hope for the millions of cancer patients worldwide who lack effective treatment options. As the leader in the field of ecDNA, Boundless Bio is the only company solely focused on treating oncogene amplified cancers. Their comprehensive approach allows them to identify and exploit the unique vulnerabilities of ecDNA in cancer cells, developing powerful new cancer medicines that disrupt the cancer cells' ability to survive. With boundless innovation and energy, their team of professional drug hunters is at the forefront of driving the discovery and development of a novel therapeutic approach to targeting oncogene amplified cancers.Generated from the website